Standout Papers

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: ... 2009 2026 2014 2020 933
  1. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial (2009)
    Joan T. Merrill, C. Michael Neuwelt et al. Arthritis & Rheumatism

Immediate Impact

22 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
2 intermediate papers

Works of Tammy O. Utset being referenced

In Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus Nephritis
2010
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Tammy O. Utset 2249 1870 713 43 3.1k
Frédéric Houssiau 2229 1189 433 44 3.1k
Maria Dall’Era 2142 1478 691 96 2.9k
Anca Askanase 2291 1536 743 127 3.1k
Holly M. Bastian 3221 2035 661 41 3.9k
Ola Nived 3244 2015 711 72 3.8k
G. Dennis 2040 1893 881 36 3.5k
Enrique de Ramón 2074 1311 469 49 3.0k
Winn Chatham 3035 2703 1719 44 4.6k
Paul Brunetta 2478 1664 1176 30 3.5k
Gian Domenico Sebastiani 2871 1818 721 103 4.0k

All Works

Loading papers...

Rankless by CCL
2026